Both Viremia and Cytokine Levels Associate with the Lack of Severe Disease in Secondary Dengue 1 Infection among Adult Chinese Patients by Tang, Yangbo et al.
Both Viremia and Cytokine Levels Associate with the
Lack of Severe Disease in Secondary Dengue 1 Infection













1Department of Laboratory Medicine, Guangzhou 8th People’s Hospital, Guangzhou Medical College, Guangzhou, China, 2State Key Laboratory of Pathogen and
Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China, 3Department of Medicine, University of Rochester, Rochester, New York, United States of
America, 4Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, United States of America, 5Institute of Tropical
Medicine, Southern Medical University, Guangzhou, China
Abstract
Secondary dengue infections are frequently associated with increased risk for dengue hemorrhagic fever and dengue shock
syndrome. Surprisingly, we observed no dengue hemorrhagic fever cases among 353 hospitalized dengue-infected patients
including 212 with primary, and 141 with secondary dengue 1 infection in China. To explore virological and immunological
mechanisms which may account for this unexpected clinical observation, we assessed dengue viremia, type I interferon and
inflammatory cytokine levels in these patients. While the levels of viremia and inflammatory cytokines are indistinguishable
between primary and secondary infections, IFNa levels are significantly higher in primary than that in secondary infection.
However, IFNa levels are positively correlated with dengue viremia levels (p,0.0001), but negatively correlated with the
platelet counts (p,0.0001) and serum ALT levels (p=0.0003). These results provide direct in vivo evidence that clinical
dengue disease severity is affected by both viral and human immune factors.
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Introduction
Dengue viruses cause dengue fever in 50–100 million people
annually, but only a small fraction of infections develop into
dengue hemorrhagic fever and dengue shock syndrome (DHF/
DSS). Some favor the idea that DHF/DSS are the result of
immunopathology caused by cross-reactive responses of T cells or
B cells [1,2]; others place a greater emphasis on viral virulence
factors [3–5]. It may be that both immune and viral factors affect
the clinical outcome of dengue fever. Nonetheless, direct evidence
on the relative contributions of immune and viral elements to
dengue disease severity is lacking, especially in adult patients. In
this study, we built on our previous observation that DHF/DSS
cases were absent among 353 hospitalized Chinese patients with
either primary or secondary dengue 1 infection (DENV1) [6] to
explore the possible virological and immunological mechanisms
that influence dengue disease severity.
Among immune factors, we focused on type I interferons, IFNa
and IFNb (IFNa/b), and a selective number of inflammatory and
anti-inflammatory cytokines. IFNa/b are often secreted rapidly
upon viral infection and provide the first-line of defense for
uninfected cells through the induction of an antiviral state [7–9].
In patients with dengue virus infection, IFNa serum levels are
elevated early [10,11], suggesting it may contribute to virological
control in vivo. In cell cultures in vitro and murine models in vivo,
IFNa and IFNb suppress early stages of dengue viral replication;
whereas the type II interferon, IFNc (produced mainly by
activated T and NK cells), limits dengue viral replication at later
stages [12–16]. IFNa and IFNb can be induced by dengue virus
infection in many cell types, but the kinetics of their induction
differs. IFNb gene activation is induced within hours of dengue
viral infection in A549 lung carcinoma cell lines and Chang Liver
cells [17]. In contrast, IFNa secretion is detected in dengue-
infected primary human monocytes and plasmacytoid dendritic
cells only 20 to 24 hours post virus inoculation [18–20]. While
both IFNa and IFNb have anti-dengue activity in vitro, previous
clinical studies had limited to the measurement of IFNa levels, and
most had been performed in subjects with either DENV2 or
DENV3 infections [10,11,21]. In the current study, we performed,
for the first time, a large-scale measurement of both IFNa and
IFNb in patients with DENV1 infection.
Cytokines that are undetectable in the blood of healthy
individuals are elevated in dengue-infected patients, such as IL-
1b, IL-2, IL-6, IL-8, IL-10, IL-13, IL-18, IFNc, TNFa, and
MCP1 [22–30]. Some of them are associated more closely with
DHF/DSS than others. In comparison to those with uncompli-
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levels of inflammatory cytokines IL-6, IL-8, and TNFa [25,31–
33], and both IL-8 and TNFa levels are independent correlates of
dengue disease severity [24,32]. The anti-inflammatory cytokine
IL-10 has also been reported as having higher levels in DHF/DSS
patients than patients with dengue fever [21,29,34]. In the current
study, we chose to examine in detail the correlation between these
host factors and viremia levels in vivo.
Materials and Methods
Study subjects and samples
The patient cohort has been described in details previously [6].
Briefly, sera or plasma samples were obtained from 353 hospitalized
patients with acute DENV1 infection during a dengue outbreak in
southern China in 2006. Dengue IgM and IgG capture ELISA kits
(Panbio, Brisbane, Queensland, Australia) were used to diagnose
primary and secondary dengue infections according to the
manufacturer’s protocol. Primary infection was diagnosed when
only anti-dengue IgM was positive. Secondary dengue infection was
diagnosed when both anti-dengue IgM and IgG were positive and
IgM/IgG ratio,1.78, or when only IgG was positive and IgG
level.22 units. By these diagnostic criteria, there were 212 patients
with primary and 141 with secondary infections in our clinical
cohort. Excluding those with HBV co-infections which account for
about 8% of the total subjects [6], 170 patients with primary
infection, and 115 patients with secondary infection were included
in the current study. Sera from 37 healthy control adults were also
collected. In 136 dengue-infected patients in whom extra serum
samples were still available at the beginning of the current study,
additional virological immunological analyses were performed.
These studies have been approved by the Guangzhou 8
th People’s
Hospital Ethics Committee review. Written informed consents were
obtained from all study subjects. National rules and regulations on
human subject protection were strictly followed.
Clinical and laboratory tests
Routine clinical tests including platelet count, liver function tests
including aspartate aminotransferase (AST) and alanine transam-
inase (ALT) were performed as we previously described [6]. Serum
interferon levels were measured using commercially available
ELISA kits for IFNa (PBL InteferonSource, Piscataway, NJ) and
IFNb (Fujirebio Diagnostics, Inc., Malvern, PA) according to the
manufacturer’s instructions. The human IFNa multi-subtype
ELISA kit detects 14 out of 15 known human IFNa subtypes
(IFN-a1, IFN-a2, IFN-a4a, IFN-a4b, IFN-aA, IFN-aB2, IFN-aC,
IFN-aD, IFN-aG, IFN-aH, IFN-aI, IFN-aJ1, IFN-aK, and IFN-
aWA) with a lower limit of detection of 12.5 pg/ml. Human
Interferon-b ELISA kit detects IFNb with a lower limit of
detection of 2.5 IU/ml. Serum cytokine levels for IL-6, IL-10,
IFNc, and TNFa were measured using commercially available
ELISA kits (Diaclone, Besancon Cedex, France) according to the
manufacturer’s instructions.
Quantification of viral RNA
Viral RNA was extracted from plasma sample using QIAamp
Viral RNA Mini kit (QIAGEN) and transcribed into cDNA using
TakaRa PrimeScript
TMRTkit (TakaRaBiotech. Ltd.,Da Lian city,
China. www.takara.com.cn). Real-time PCR assay was then
performed using TakaRa Premix Ex Taq
TM (TakaRa Biotech.
Ltd.) on an ABI7300 real-time PCR system (ABI, Foster city, CA).
The primer and probe sequences were designed based on DENV1
isolated in Guangzhou (GenBank Accession #EU280167). The
primers used were as follows: forward primer, 59AAGGACTA-
GAGGTTAGAGGAGACCC39 (nucleotides 10589 to 10613);
reverse primer, 59 CGTTCTGTGCCTGGAATGATG 39 (nucle-
otides 10697 to 10677); and probe, FAM-59 TCTGGTCTCTCC-
CAGCGTCAATATGCTGTT 39-TAMRA (nucleotides 10657 to
10628) (where FAM is the reporter and TAMRA is the quencher).
cDNA synthesis was performed in a total volume of 10ml containing
2mlo f5 6PrimeScript buffer, 0.5ml of PrimeScript RT enzyme MixI,
2ml of random hexamer (100mM), 0.5ml of Oligo dT primer (50mM) ,
2mlo fv i r a lR N A ,a n d3 ml of RNase free dH2O. The RT conditions
were 37u for 15m, followed by 85u for 5s. The PCR reaction was
performed ina total volume of 20ml containing 10mlo f2 6Premix Ex
Taq, 0.4ml of forward primer (10mM), 0.4ml of reverse primer
(10mM), 0.8mlo fP r o b e( 5 mmol/L), 0.4mlo f5 0 6ROX reference dye,
2mlo fc D N A ,a n d6 ml of RNase free dH2O. The PCR conditions
were 95u for 30 s, followed by 40 cycles of 95u for 5s and 60u for 31s.
A standard curve was established using a 10-fold serial dilution of
plasmid DNA containing 10
3 to 10
9 copies of DENV1 genome. The
lower limit of detection is 100 copies/ml. The viremia level of each
patient sample was calculated according to the standard curve.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
Version 4.0 (GraphPad Software, San Diego, CA). One-way
analysis of variance (ANOVA) was used for mean comparison
from multiple groups. Association between two laboratory
outcomes was analyzed by Spearman rank correlation coefficient.
A statistical test with P-value,0.05 was considered significant in
mean comparison, or in correlation analysis.
Results
Clinical characteristics of patients with primary and
secondary DENV1 infections
ExcludingthosewithHBV-co-infections and thosewithincomplete
clinical or laboratory data, 285 dengue-infected patients were
included in this analysis. Among these patients, 170 and 115 had
primary and secondary dengue infections, respectively. Key demo-
graphic characteristics of these two patient groups were summarized
in Figure 1.P a t i e n t sw i t hs e c o n d a r yi n f e c t i o na r eo l d e rt h a nt h o s e
with primary infections (41.3616.6 years vs. 33.2615.6 years,
p,0.0001, Fig. 1a) and have fever for a longer period of time
(5.461.9 days vs. 4.861.8 days, p=0.0216, Fig. 1b). This might due
to the fact that adults usually do not go to hospital at the beginning of
their illness, so samples were collected from them later than from
younger patients, and older patients are more likely to have
experienced dengue infection previously than younger patients. It is
i n t e r e s t i n gt on o t et h a tw h i l et h ep l a t e l e tc o u n t sw e r en o td i f f e r e n t
between the two groups (76.1652.6610
3 /ml vs. 83.0652.2610
3 /
ml, p=0.1483, Fig. 1c), the average prothrombin time (PT) was
shorter in those with secondary infection (11.2560.83 s
vs.11.8161.36 s, p=0.0003, Fig. 1d). Both patient groups have
higher AST (primary: 106.5694.1 U/L; secondary: 104.1676.0 U/
L) and ALT (primary: 73.4683.0 U/L; secondary: 77.6665.6 U/L)
levels than healthy uninfected controls (AST: 24.265.2 U/L; ALT:
20.668.2 U/L,p,0.001), but similar levels to each other (Fig. 1e, f).
Immunological and viralogical features of patients with
primary and secondary DENV1 infections
To examine what else might be different between primary and
secondary DENV1 infections, we next assessed the secretion of
type I interferons and a selective number of inflammatory and
anti-inflammatory cytokines in these patients. Figure 2 shows that
all dengue infected patients had secreted higher levels of IFNa
than uninfected healthy controls (primary: 18.5 (0.0,2392) pg/ml;
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p,0.0001) and patients with primary infection had significantly
higher IFNa levels than those with secondary infection (p,0.01)
(Fig. 2a). In contrast, few infected subjects made substantial
amounts of IFNb (primary: 0.0(0,199.2) IU/ml; secondary:
0.0(0.0,104.3) IU/ml) and the IFNb levels are not statistically
higher than that in uninfected controls (control: 0.0(0.0,158.4)
IU/ml) (Fig. 2b). While patients with both primary and secondary
infections produced large amounts of inflammatory cytokines
including IFNc, TNFa and IL-6 than uninfected controls
(p,0.001), there are no differences between the two patient
groups (Fig. 2c, d, e); the same holds true for the anti-
inflammatory cytokines, IL-10 (Fig. 2f).
In patients who had an additional vial of plasma sample
available after all other clinical and immunological assays were
performed, we also measured viremia levels using real-time
quantitative PCR as described in the Materials and Methods.
These include 79 patients with primary and 57 patients with
secondary infection. Results show a lack of difference in viremia








6) copies/ml p=0.1170, Fig. 3). Further analysis of the
association between viremia levels and fever onset days (fever onset
day is defined as the duration from the time when patients first
experienced fever symptom to the time when they were
hospitalized and samples were collected) showed that in both
patient groups, viremia levels rapidly decreased within 8 days of
fever onset when analyzed together (Fig. 4c) or separated into two
subsets with either primary or secondary infections (Fig. 4a, b).
IFNa levels are associated with multiple facets of dengue
disease
To gain further insight into the interpretation of various clinical
and laboratory measurements obtained, we performed Spearman
correlation analysis on a number of parameters that could
theoretically affect disease severity. Unexpectedly, we found viremia
levels to be positively correlated with the levels of antiviral cytokine
IFNa either for the entire group of 136 patients (r=0.6446,
p,0.0001, Fig. 5c), or two subsets with primary (=79) and
secondary (n=57) infections (Fig. 5a, b). This positive correlation
becomes more significant when only those with viral load greater
than 1,000 copies/ml were included in the analysis (primary=51,
secondary=29, total=80, r=0.7733, p,0.0001, data not shown).
Also unexpected was that the IFNa levels were negatively correlated
with platelet counts (r=20.2327, P,0.0001, Fig. 6a). In addition,
IFNa levels were negatively correlated with serum ALT levels
(r=20.2112,P=0.0003,Fig. 6b), but not with AST levels (Fig.6c).
Temporal secretion of IFNa, IFNc, and IL-10 during
dengue fever
We and other have found that many cytokines that are
undetectable in the blood of healthy individuals are significantly
elevated in dengue-infected patients [6,22–30]. The interplay
between type I interferons and these other cytokines may affect the
Figure 1. Demographic and clinical characteristics of patients with primary and secondary DENV1 infections. The age (a), fever onset
day (b), platelet counts (c), PT (d), AST (e) and ALT levels (f) were summarized from 170 patients with primary and 115 patients with secondary DENV1
infections. Included also are AST and ALT levels from 37 healthy controls for comparison (e, f). Each dot represents one subject.
doi:10.1371/journal.pone.0015631.g001
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measurable at high levels in a large proportion of DENV1-infected
subjects, and IFNb was mostly undetectable, we next analyzed the
kinetics of IFNa secretion in association with that of a pro-
inflammatory cytokine, IFNc, and an anti-inflammatory cytokine,
IL-10. Figure 7 shows a cross-sectional analysis between fever
onset days and the median cytokine levels (left Y-axis), as well as
the proportion of subjects who had a detectable level of cytokine
responses in all 285 of DENV1-infected patients (right Y-axis).
The median of IFNa level (182pg/ml) peaked on day 2 after fever
onset and then decreased rapidly. Likewise, the percentage of
patients who had low but detectable levels of IFNa ($12.5pg/ml)
was high on day 0 (within the first 24 hours of fever onset) (67%)
and reached peak level on day 3 (84%) (Fig. 7a). The elevation of
IFNc levels followed the induction of IFNa and reached its peak
level on days 3–4. In parallel, most subjects had detectable IFNc
on days 5–6 (Fig. 7b). In contrast, the IL-10 response only
reached peak level by day 6 (142pg/ml), although a large
proportion of subjects had detectable IL-10 secretion between
days 2–6, an indication that IL-10 producers might be biologically
more heterogeneous in the context of dengue viral infection
(Fig. 7c). The same pattern of early IFNa secretion and late IL-10
production also holds true when similar analyses were performed
by using patients with primary and secondary dengue infections
separately (Fig.S1).
Discussion
Both IFNa and IFNb have anti-dengue activity in cell cultures in
vitro and in animal models in vivo. However, previous clinical studies
have only examined IFNa levels in the context of either DENV2 or
DENV3 infections [10,11,21]. In the current study, by carefully
Figure 3. Lack of difference in viremia levels between patients
with primary and secondary DENV1 infections. The plasma
dengue viremia levels were measured in 79 patients with primary and
57 patients with secondary dengue infections using real-time qPCR as
described in the Materials and Methods. Each dot represents one
subject.
doi:10.1371/journal.pone.0015631.g003
Figure 2. Distinctive patterns of cytokine production in patients with primary and secondary DENV1 infections. The serum levels of
various cytokines including IFNa (a), IFNb (b), IFNc (c), TNFa (d), IL-6 (e), and IL-10 (f) from 170 patients with primary and 115 patients with secondary
DENV1 infections and 37 healthy controls were presented. Each dot represents one subject. Except for IFNb which was expressed as IU/ml, all other
results were expressed as pg/ml.
doi:10.1371/journal.pone.0015631.g002
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infected adult patients, we found, for the first time, that IFNa levels
are more significantly elevated than IFNb during dengue fever.
Moreover,inindividuals with DENV1infection,theIFNa elevation
appears early, followed by the induction of a pro-inflammatory
cytokine IFNc, and lastly an anti-inflammatory cytokine IL-10.
Unexpectedly, the levels of IFNa are directly proportional to
viremia levels and the degree of thrombocytopenia.
A differential induction of IFNa and IFNb in patients with
dengue fever has never been reported before. This phenomenon is
similar to that of acute HIV infection during which IFNa but not
IFNb level was rapidly, and transiently, elevated [35]. The exact
reason for why only IFNa was made substantially in dengue and
HIV-infected patients is not known, but it may be related to the
fact that IFNa and IFNb are produced by different cell types.
IFNa is mainly produced by lymphoid cells, while IFNb is made
primarily by non-lymphoid cells. Since the principal dengue target
cells are monocytic cells including monocyte, macrophage and
dendritic cells [36–38] and HIV infects macrophage and CD4+ T
cells, it may be expected that dengue and HIV infections directly
stimulate relevant human cells to make IFNa, but not IFNb.
Nonetheless, IFNb may be secreted subsequent to immune
activation through either IFNa or other yet to be identified
factors during viral infections. It is interesting to note that the
temporal sequence of cytokine secretion is also similar between
acute dengue and acute HIV infections, in that IFNa is made first,
followed by the secretion of inflammatory cytokines, and lastly the
anti-inflammatory cytokine IL-10 [35].
A significant increase in IFNa levels may contribute to the
efficient control of dengue virus replication, but may also exert
undesirable immune-regulatory effects on successive immune
responses and thus play a more complex role in the pathogenesis
of dengue fever. Unexpectedly, we observed that levels of IFNa
were negatively correlated with platelet counts but positively
correlated with viremia levels. These results suggest that elevated
IFNa might be one of the factors contributing to decreased platelet
Figure 4. Rapid viremia decay in both primary and secondary DENV1 infections. The plasma dengue viremia levels over time were
analyzed in 79 patients with primary (a) and 57 patients with secondary (b) dengue infections separately, or together (c). Each dot represents one
subject. The fever onset day is defined as the duration from the time when patients first experienced fever symptom to the time when they were
hospitalized and samples were collected.
doi:10.1371/journal.pone.0015631.g004
Figure 5. Positive correlation between viremia and IFNa levels in both primary and secondary DENV1 infections. The correlations
between IFNa levels and plasma dengue viremia levels were analyzed in 79 patients with primary (a) and 57 patients with secondary (b) dengue
infections separately, or together (c). Each dot represents one subject.
doi:10.1371/journal.pone.0015631.g005
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platelet count during dengue virus infection is clearly due to
multiple factors. For instance, it has been reported that IFNa2b
could induce thrombocytopenia through the inhibition of platelet
production from human megakaryocytes [39]. Our current finding
may help to explain why patients with DHF have higher levels of
IFNa than those with dengue fever [10]. In this regard, it is worth
noting that persistent activation of IFNa gene in human peripheral
blood mononuclear cells by another arbovirus, chikungunya,
correlates with chronic disease [40,41], and plasma viral loads and
IFNa levels are directly proportional in chikungunya virus infected
adults [42].
It is paradoxical that antiviaral IFNa levels shoud have a
postitive correlation with viremia levels in vivo. This highlights the
intricate interactions between a host immune factor and dengue
viral replication. Although the precise reason for this is unclear,
the time of sample collection may determine what type of
correlations will be observed. In an experimental dengue infection
system, we detected IFNa/b secretion immediately after virus
production in DENV2-infected primary human monocytes,
however, the kinetics of IFNa/b secretion was temporally
associated with the decrease of virus production over a 5 day
period (Kou, Virology, in press). A similar temporal association
between viremia and IFNa secretion has also been reported in
DENV3-infected Thai children [11]. Thus, our data offer a snap-
shot of the dynamic interactions between dengue viral replicaiton
and IFNa-mediated host defense mechanisms, and should not be
interpreted as IFNa does not control virus replication.
It is interesting to note that IFNc, IL-6 and IL-8 levels were
found to be higher in secondary than primary infections in a
recent study of dengue-infected patients in Western India [43]. In
our current study, none of the cytokines measured including IFNc,
TNFa, IL-6 and IL-10 were statistically significantly different
between patients with primary and secondary infections. The
contrasting results may be explained by variability in dengue
serotypes and the timing of sample collection. Our patients were
Figure 6. Levels of IFNa were negatively correlated with platelet counts and serum ALT levels. In the same cohort of 285 subjects with
dengue fever due to either primary or secondary infection, the correlations between IFNa levels and platelet counts (a), ALT levels (b), and AST levels
(c) were analyzed using Spearman rank correlation test. IFNa levels showed a significant negative correlation with platelet counts (r=20.2327,
P,0.0001) (a), and serum ALT levels (r=20.2122, P=0.0003) (b), but not serum AST levels (c). Each dot represents one subject.
doi:10.1371/journal.pone.0015631.g006
Figure 7. Temporal secretion of IFNa, IFNc, and IL-10 during dengue fever. The associations between fever day and cytokine secretion
including (a) IFNa, (b) IFNc, and (c) IL-10 were analyzed in 285 subjects with dengue fever. The dashed line represents the median of cytokine levels,
and the solid line indicates the percentage of subjects who had a positive cytokine level. Each symbol represents the median or average value at
indicated time point.
doi:10.1371/journal.pone.0015631.g007
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their patients were infected by all 4 DENV serotypes and a third of
whom had DHF. Additionally, a large number of patients in our
cohort had cytokine levels in the range of hundreds to thousands
(pg/ml) because we enrolled most patients early after the onset of
symptoms, whereas the majority of their patients had cytokine
levels in the tens and a few of them in the hundreds (pg/ml)
because nearly half of their patients were recruited late after the
onset of illness [43]. Moreover, it is possible that the genetic
differences between the Indian and Chinese populations have
contributed to the observed discrepancy between these two studies.
In summary, we compared the levels of viremia, IFNa/b, and a
selective number of cytokines in a large cohort of acutely DENV1
infected patients with either primary or secondary infection. Our
results suggest that a lack of severe disease in this cohort of
secondary DENV1 infected adults could be explained in part by
both immune and virologic factors. It may also be possible that
unique viral factors such as virus strain or genetic factors such as
HLA alleles in the population could affect clinical presentation
significantly. These should be focus of future studies. Overall, our
findings not only advanced the understanding of human dengue
pathophysiology, but also had implication in developing new anti-
dengue therapeutics.
Supporting Information
Figure S1 Temporal secretion of IFNa, IFNc, and IL-10 in
patients with dengue fever. The associations between fever day
and cytokine secretion including IFNa (a, b) IFNc (d, e), and IL-10
(g, h) were analyzed in either in 170 subjects with primary dengue
infection (a, d, g), in 115 subjects with scondary dengue infection
(b, e, h). The dashed line represents the median of cytokine levels,
and the solid line indicates the percentage of subjects who had a
detectable cytokine level. Each symbol represents the median or
average value at indicated time point.
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